Effect of a recombinant HIV gp160 vaccine on monokine production.
An investigation was undertaken to determine whether a recombinant gp160 envelope protein, which is currently being evaluated as a vaccine for AIDS, induces or modulates the production of tumour necrosis factor-alpha (TNF-alpha) or interleukin-1 beta (IL-1 beta). Incubation of monocytes from healthy, HIV-seronegative persons with 0.0001-1.0 micrograms of the recombinant vaccine did not result in the secretion of TNF-alpha or IL-1 beta, nor did the recombinant product augment or suppress monokine production by lipopolysaccharide (LPS) stimulated monocytes. The vaccine was also without a stimulatory or modulatory effect upon TNF-alpha or IL-1 beta secretion by monocytes from a patient with the AIDS-related complex (ARC) and from the monocytic THP-1 cell line. The lack of effect of gp160 on monokine production has important implications for its efficacy as a vaccine for AIDS.
Dooley
D P
DP
Department of Research Immunology, San Antonio State Chest Hospital, TX 78223.
Cox
R A
RA
Looney
D J
DJ
D015686:Gene Products, env / Q000494:pharmacology*; D006678:HIV / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000494:pharmacology; D009000:Monocytes / Q000378:metabolism; D011498:Protein Precursors / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*; D014765:Viral Vaccines / Q000494:pharmacology*
D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D007375:Interleukin-1; D008070:Lipopolysaccharides; D011498:Protein Precursors; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014765:Viral Vaccines